BiotechTube

LY2495655 + Placebo

Phase 2Completed
1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Muscular Atrophy

Conditions

Muscular Atrophy

Trial Timeline

Jul 1, 2011 → Feb 1, 2014

NCT ID
NCT01369511

About LY2495655 + Placebo

LY2495655 + Placebo is a phase 2 stage product being developed by Eli Lilly for Muscular Atrophy. The current trial status is completed. This product is registered under clinical trial identifier NCT01369511. Target conditions include Muscular Atrophy.

What happened to similar drugs?

20 of 20 similar drugs in Muscular Atrophy were approved

Approved (20) Terminated (3) Active (0)
✅GoserelinAstraZenecaApproved
✅Sugammadex 2 mg/kg + Sugammadex 4 mg/kg + Sugammadex 16 mg/kg + Neostigmine + Glycopyrrolate + Rocuronium + VecuroniumMerckApproved
✅Deep neuromuscular block + Moderate neuromuscular blockMerckApproved
✅Sugammadex + RocuroniumMerckApproved
✅sufficient dose of rocuronium + sugammadex 10 min after position changeMerckApproved
✅neostigmine/glycopyrrolate + sugammadexMerckApproved
✅Sugammadex 2 mg/kg + Sugammadex 4 mg/kg + Neostigmine + Glycopyrrolate + Neostigmine + AtropineMerckApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT01604408Phase 2Completed
NCT01369511Phase 2Completed
NCT01341470Phase 1Completed

Competing Products

20 competing products in Muscular Atrophy

See all competitors
ProductCompanyStageHype Score
Phase 1, SQY51 + Phase 2a, SQY51 (cohort 1) + Phase 2a, SQY51 (cohort 2) + Phase 2a, SQY51 (cohort 3)BiotrialPhase 1/2
29
ENTR-601-44 + ENTR-601-44 - matching placeboEntrada TherapeuticsPhase 1/2
29
ENTR-601-45 + ENTR-601-45 - matching placeboEntrada TherapeuticsPhase 1/2
29
Tadalafil + PlaceboEli LillyPhase 3
32
DS-5141bDaiichi SankyoPhase 2
39
DS-5141bDaiichi SankyoPhase 1/2
32
Bocidelpar + PlaceboAstellas PharmaPhase 1
21
scAAV9.U7.ACCAAstellas PharmaPhase 1/2
32
Placebo + Reldesemtiv 150 mg + Reldesemtiv 450 mgAstellas PharmaPhase 2
35
HRS-9190; under Inhalational Anesthesia + HRS-9190; under Intravenous Anesthesia + Cisatracurium (under Inhalational Anesthesia). + Cisatracurium (under Intravenous Anesthesia)Jiangsu Hengrui MedicinePhase 2
42
HRS-9190 + HRS-9190 + HRS-9190 + HRS-9190 + Rocuronium + RocuroniumJiangsu Hengrui MedicinePhase 2
42
HRS-9190 + HRS-9190 + HRS-9190Jiangsu Hengrui MedicinePhase 2
35
NS-065/NCNP-01Nippon ShinyakuPhase 2
35
Viltolarsen + PlaceboNippon ShinyakuPhase 3
40
ViltolarsenNippon ShinyakuPhase 2
35
NS-089/NCNP-02 + NS-089/NCNP-02Nippon ShinyakuPhase 2
39
NS-065/NCNP-01Nippon ShinyakuPhase 1
29
NS-050/NCNP-03 + PlaceboNippon ShinyakuPhase 1/2
39
NS-089/NCNP-02Nippon ShinyakuPhase 2
42
ViltolarsenNippon ShinyakuPhase 3
36